Psychol Med. 1992 May;22(2):347-52.

Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.

Source

Queen Street Mental Health Centre, Psychology and Biometrics Section, Toronto, Canada.

Abstract

The schizophrenic patient's early psychological response to neuroleptic treatment has been demonstrated to be a significant predictor of treatment response. The validity of the construct of subjective response is evaluated by comparison of two measures. Fifty-five recently admitted and unmedicated schizophrenic patients were randomly allocated to chlorpromazine or haloperidol. Subjective responses at 24 and 48 hours as assessed by two different scales, the Van Putten & May scale and the self-administered Drug Attitude Inventory, were strongly correlated with outcome at three weeks. Early emergence of extrapyramidal symptoms was not related to subjective response, but dysphoric patients had a greater incidence of EPS by the end of treatment than did non-dysphoric patients. The two measures showed high concordance in identification of early drug dysphoria.

PMID:: 1615101; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Medical

Schizophrenia - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. [Int Clin Psychopharmacol. 1994]
Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
Mauri MC, Vita A, Giobbio GM, Ferrara A, Dieci M, Bitetto A, Altamura AC. Int Clin Psychopharmacol. 1994 Spring; 9(1):3-7.
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. [Arch Gen Psychiatry. 1998]
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Tollefson GD, Sanger TM, Lu Y, Thieme ME. Arch Gen Psychiatry. 1998 Mar; 55(3):250-8.
Subjective response to neuroleptics in schizophrenia. [Schizophr Bull. 1993]
Subjective response to neuroleptics in schizophrenia.
Awad AG. Schizophr Bull. 1993; 19(3):609-18.
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. [Encephale. 2005]
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, et al. Encephale. 2005 Mar-Apr; 31(2):235-46.
Review Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. [Int Clin Psychopharmacol. 1996]
Review Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.
Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP. Int Clin Psychopharmacol. 1996 May; 11 Suppl 2:55-9.

See reviews... See all...

Cited by 7 PubMed Central articles

Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing. [Environ Health Prev Med. 2008]
Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing.
Kuroda N, Sun S, Lin CK, Morita N, Kashiwase H, Yang F, Nakatani Y. Environ Health Prev Med. 2008 Sep; 13(5):288-95. Epub 2008 Aug 12.
Implicit versus explicit attitudes toward psychiatric medication: Implications for insight and treatment adherence. [Schizophr Res. 2009]
Implicit versus explicit attitudes toward psychiatric medication: Implications for insight and treatment adherence.
Rüsch N, Todd AR, Bodenhausen GV, Weiden PJ, Corrigan PW. Schizophr Res. 2009 Jul; 112(1-3):119-22. Epub 2009 May 1.
Review Methodological issues in current antipsychotic drug trials. [Schizophr Bull. 2008]
Review Methodological issues in current antipsychotic drug trials.
Leucht S, Heres S, Hamann J, Kane JM. Schizophr Bull. 2008 Mar; 34(2):275-85. Epub 2008 Jan 29.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Subjective response to neuroleptics and outcome in schizophrenia: a re-examinati...
Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.
Psychol Med. 1992 May ;22(2):347-52.

PubMed
Chromatin dynamics in interphase cells revealed by tracking in a two-photon exci...
Chromatin dynamics in interphase cells revealed by tracking in a two-photon excitation microscope.
Biophys J. 2005 Dec ;89(6):4275-85. Epub 2005 Sep 8 .

PubMed
Genes in canine articular cartilage that respond to mechanical injury: gene expr...
Genes in canine articular cartilage that respond to mechanical injury: gene expression studies with Affymetrix canine GeneChip.
J Hered. 2005 ;96(7):821-8. Epub 2005 Sep 8 .

PubMed
Human vault-associated non-coding RNAs bind to mitoxantrone, a chemotherapeutic ...
Human vault-associated non-coding RNAs bind to mitoxantrone, a chemotherapeutic compound.
Nucleic Acids Res. 2005 Sep 8 ;33(15):4874-81. Print 2005 .

PubMed
3-phosphoinositide-dependent protein kinase-1 activates the peroxisome prolifera...
3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation.
Mol Endocrinol. 2006 Feb ;20(2):268-78. Epub 2005 Sep 8 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 7 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information